ABRYSVO® Highlights

(Respiratory Syncytial Virus Vaccine)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ABRYSVO safely and effectively. See full prescribing information for ABRYSVO.

ABRYSVO (Respiratory Syncytial Virus Vaccine) for injection, for intramuscular use
Initial U.S. Approval: 2023

RECENT MAJOR CHANGES

Indications and Usage (1.3)

10/2024

Dosage and Administration (2.2)

7/2024

INDICATIONS AND USAGE

ABRYSVO is a vaccine indicated for

•
Active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. (1.1)
•
Active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older. (1.2)
•
Active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV. (1.3)

DOSAGE AND ADMINISTRATION

•
For intramuscular use. (2)
•
After reconstitution, a single dose of ABRYSVO is either 0.5 mL (Act-O-Vial presentation and vial and vial presentation) or approximately 0.5 mL (vial and prefilled syringe presentation). (2.1)

DOSAGE FORMS AND STRENGTHS

For injection.

•
For the Act-O-Vial presentation, a single dose after reconstitution is 0.5 mL. (3)
•
For the vial and prefilled syringe presentation, a single dose after reconstitution is approximately 0.5 mL. (3)
•
For the vial and vial presentation, a single dose after reconstitution is 0.5 mL. (3)

CONTRAINDICATIONS

History of severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO. (4)

WARNINGS AND PRECAUTIONS

 
Potential risk of preterm birth. To avoid the potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer ABRYSVO as indicated in pregnant individuals at 32 through 36 weeks gestational age. (5.1)

ADVERSE REACTIONS

•
The most commonly reported solicited local and systemic adverse reactions in pregnant individuals (≥10%) were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%). (6.1)
•
The most commonly reported solicited local and systemic adverse reactions in individuals 60 years of age and older (≥10%) were fatigue (15.7%), headache (12.9%), pain at the injection site (10.7%), and muscle pain (10.2%). (6.1)
•
The most commonly reported solicited local and systemic adverse reactions in individuals 18 through 59 years of age (≥10%) were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%). (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or VAERS at 1-800-822-7967 or http://vaers.hhs.gov.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 10/2024

Find ABRYSVO® medical information:

Find ABRYSVO® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

ABRYSVO® Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ABRYSVO safely and effectively. See full prescribing information for ABRYSVO.

ABRYSVO (Respiratory Syncytial Virus Vaccine) for injection, for intramuscular use
Initial U.S. Approval: 2023

RECENT MAJOR CHANGES

Indications and Usage (1.3)

10/2024

Dosage and Administration (2.2)

7/2024

INDICATIONS AND USAGE

ABRYSVO is a vaccine indicated for

•
Active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. (1.1)
•
Active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older. (1.2)
•
Active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV. (1.3)

DOSAGE AND ADMINISTRATION

•
For intramuscular use. (2)
•
After reconstitution, a single dose of ABRYSVO is either 0.5 mL (Act-O-Vial presentation and vial and vial presentation) or approximately 0.5 mL (vial and prefilled syringe presentation). (2.1)

DOSAGE FORMS AND STRENGTHS

For injection.

•
For the Act-O-Vial presentation, a single dose after reconstitution is 0.5 mL. (3)
•
For the vial and prefilled syringe presentation, a single dose after reconstitution is approximately 0.5 mL. (3)
•
For the vial and vial presentation, a single dose after reconstitution is 0.5 mL. (3)

CONTRAINDICATIONS

History of severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO. (4)

WARNINGS AND PRECAUTIONS

 
Potential risk of preterm birth. To avoid the potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer ABRYSVO as indicated in pregnant individuals at 32 through 36 weeks gestational age. (5.1)

ADVERSE REACTIONS

•
The most commonly reported solicited local and systemic adverse reactions in pregnant individuals (≥10%) were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%). (6.1)
•
The most commonly reported solicited local and systemic adverse reactions in individuals 60 years of age and older (≥10%) were fatigue (15.7%), headache (12.9%), pain at the injection site (10.7%), and muscle pain (10.2%). (6.1)
•
The most commonly reported solicited local and systemic adverse reactions in individuals 18 through 59 years of age (≥10%) were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%). (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or VAERS at 1-800-822-7967 or http://vaers.hhs.gov.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 10/2024
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.